Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1508 ARTÍCULOS , VIENDO DEL 1486 AL 1500

AMPK in Neurodegenerative Diseases

Domise M, Vingtdeux V.

Exp Suppl. 2016;107:153-177. doi: 10.1007/978-3-319-43589-3_7.

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review

Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD.

Oxid Med Cell Longev. 2016;2016:8590578. doi: 10.1155/2016/8590578. Epub 2016 Dec 27.

Eye movements in neurodegenerative diseases

MacAskill MR, Anderson TJ.

Curr Opin Neurol. 2016 Feb;29(1):61-8. doi: 10.1097/WCO.0000000000000274.

[Paraneoplastic Neurological Syndrome with Dementia]

Tanaka K.

Brain Nerve. 2016 Apr;68(4):391-8. doi: 10.11477/mf.1416200411.

Fragile X tremor ataxia syndrome and white matter dementia

Filley CM.

Clin Neuropsychol. 2016 Aug;30(6):901-12. doi: 10.1080/13854046.2016.1165805. Epub 2016 Jun 29.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN).

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0. Epub 2016 Oct 21.

The rationale for deep brain stimulation in Alzheimer's disease

Mirzadeh Z, Bari A, Lozano AM.

J Neural Transm (Vienna). 2016 Jul;123(7):775-783. doi: 10.1007/s00702-015-1462-9. Epub 2015 Oct 6.

Prevalence and treatment pattern of Parkinson's disease dementia in Korea

Oh YS, Kim JS, Park IS, Shim YS, Song IU, Park JW, Lee PH, Lyoo CH, Ahn TB, Ma HI, Kim YD, Koh SB, Lee SJ, Lee KS.

Geriatr Gerontol Int. 2016 Feb;16(2):230-6. doi: 10.1111/ggi.12457. Epub 2015 Feb 5.

Olfaction deterioration in cognitive disorders in the elderly

Ottaviano G, Frasson G, Nardello E, Martini A.

Aging Clin Exp Res. 2016 Feb;28(1):37-45. doi: 10.1007/s40520-015-0380-x. Epub 2015 May 24.

Impaired capacity for prospection in the dementias--Theoretical and clinical implications

Irish M, Piolino P.

Br J Clin Psychol. 2016 Mar;55(1):49-68. doi: 10.1111/bjc.12090. Epub 2015 May 27.

Parkinson's disease (PD) with dementia and falls is improved by AChEI? A preliminary study report

Lauretani F, Galuppo L, Costantino C, Ticinesi A, Ceda G, Ruffini L, Nardelli A, Maggio M.

Aging Clin Exp Res. 2016 Jun;28(3):551-5. doi: 10.1007/s40520-015-0437-x. Epub 2015 Aug 21.

Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases

Shetty AK, Bates A.

Brain Res. 2016 May 1;1638(Pt A):74-87. doi: 10.1016/j.brainres.2015.09.019. Epub 2015 Sep 28.

Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales

Gasser AI, Calabrese P, Kalbe E, Kessler J, Rossier P.

Rev Neurol (Paris). 2016 Feb;172(2):138-45. doi: 10.1016/j.neurol.2015.08.004. Epub 2015 Oct 20.

Parkinson's and Alzheimer's diseases: Focus on mild cognitive impairment

Korczyn AD.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S159-61. doi: 10.1016/j.parkreldis.2015.09.053. Epub 2015 Oct 19.

Purinergic receptors as potential therapeutic targets in Alzheimer's disease

Woods LT, Ajit D, Camden JM, Erb L, Weisman GA.

Neuropharmacology. 2016 May;104:169-79. doi: 10.1016/j.neuropharm.2015.10.031. Epub 2015 Oct 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias